Physician profile
Scott Rosenberg
NPI 1063461614
$7,665.44
in general payments reported to CMS, 2019-2025
36 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $307 · 2021: $736 · 2022: $1,066 · 2023: $1,543 · 2024: $1,241 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,329 · Education: $45.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,328.60 |
| Education | $45.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,584.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,177.22 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Genzyme Corporation | $679.45 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $482.69 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $445.98 | 2019-2025 | |
| Genentech USA, INC. | $330.09 | 2019-2025 | Xolair |
| Harmony Biosciences LLC | $318.11 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.08 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Amgen INC. | $203.37 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $197.94 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $190.77 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Insmed, INC. | $168.13 | 2019-2025 | Arikayce |
| Verona Pharma, INC. | $167.71 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $147.86 | 2019-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $140.88 | 2019-2025 | Uptravi, Opsumit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $111.04 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $107.15 | 2022-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $97.72 | 2019-2025 | |
| Electromed, INC. | $95.03 | 2019-2025 | Smartvest |
| Inspire Medical Systems, INC. | $92.62 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $84.76 | 2021-2024 | Aralast |
| Teva Pharmaceuticals USA, INC. | $84.21 | 2019-2022 | |
| Pfizer INC. | $61.77 | 2019-2025 | |
| Sanofi Pasteur INC. | $54.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $45.99 | 2023 | |
| Mylan Specialty L.P. | $45.11 | 2019-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $42.41 | 2025 | Purified Cortrophin Gel |
| Resmed Corp | $40.03 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.13 | 2019-2023 | |
| Pulmonx Corporation | $28.61 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Vapotherm INC | $24.35 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.67 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.73 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.60 | 2025 | Horizant |
| Lilly USA, LLC | $16.21 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $13.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.